This document discusses intellectual property protections for pharmaceutical products under the Trans-Pacific Partnership Agreement (TPPA). It references statements from organizations like PhRMA, Public Citizen, and IGBA on the IP rules in the TPPA. The document notes transition periods for certain countries to implement TRIPS-Plus patent and data provisions for pharmaceuticals. It includes tables on international patent applications from TPPA countries and in the Western Hemisphere. The document uses Latin phrases and citations throughout to reference other documents and sections.

1. project
documents
Ensuring incentives for innovation
and access to medicines
The balance struck in the Trans-Pacific Partnership
Agreement on intellectual property
(patent and regulatory data)
protection for pharmaceutical products
Rosine M. Plank-Brumback

6. Pharmaceutical Research and Manufacturers of America (PhRma)
Public Citizen's Global Access to Medicines
International Generic and Biosimilar Medicines Association (IGBA)
PhRMA Statement on the Transpacific Partnership Negotiations
TPP Transition Periods on Pharmaceutical Intellectual Property Rules: Bad
Rules Coming Soon in a TPP Country Near You
See
Working Session 10:
Principles to Foster Trade in Generic and Biosimilar Medicines

8. available at

9. —

10. inter alia
et al

11. inter alia
e.g.
e.g.

14. per se

15. United States Section 337 of the Tariff Act of 1930
Id
Id
Id
inter alia

16. inter
alia

17. ordre public

18. sui generis
•

19. •
•
e.g

20. Supra

21. Id.
Id.,
Id
see

22. inter alia
•
•
•
Supra

27. supra

28. pro tempore

29. see
Supra
BIO Statement on Data Exclusivity Provisions Within the Trans-Pacific Partnership

30. supra

31. •
•
•
•

32. •
•
•
•
•
•
•
•

33. •
•
•
•
•
•
•
•
Supra

34. •
•
inter alia
•
•
supra

35. •
•
•
•
•
inter alia
supra

36. •
•
•
•
See supra

38. Wall Street Journal
Wall Street Journal

41. supra
supra see supra
The SciTech Lawyer
supra supra

42. Id.
The Economist
See
The Economist

44. •
•
•

45. •
ordre public
•
•
•
•
•

46. •
•
•
•
•

47. •
•
•
•
•

48. inter alia
• Protocol
Amending the TRIPS Agreement, i.e.
•
•

49. e.g.
marketing approval granted in another territory
the first marketing approval relied on.”
US-Peru FTA i.e. a reasonable period of time
which shall normally mean 5 years.
Con excepción de patentes farmacéuticas

50. inter alia

52. et al

53. inter alia

54. Supra

55. See

56. The
Economist

58. available
on request at
et al

61. Table A.1
International applications filed under the Patent Cooperation Treaty (PCT) from TPP States
Canada
Chile
Mexico
Peru
United States
Total TPP

62. Table A.2
International applications filed under the PCT
from western hemisphere (OAS Member) States
Chile
Mexico
Peru
Total Latin America and Caribbean
Canada
United States
Total Western Hemisphere

63. Table A.3
Transition periods for implementing certain (TRIPS-Plus)
patent and data provisions for pharmaceutical products
under the TPPA